Literature DB >> 32255874

A model for HIV/AIDS pandemic with optimal control.

Amiru Sule1, Farah Aini Abdullah1.   

Abstract

Human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS) is pandemic. It has affected nearly 60 million people since the detection of the disease in 1981 to date. In this paper basic deterministic HIV/AIDS model with mass action incidence function are developed. Stability analysis is carried out. And the disease free equilibrium of the basic model was found to be locally asymptotically stable whenever the threshold parameter (RO) value is less than one, and unstable otherwise. The model is extended by introducing two optimal control strategies namely, CD4 counts and treatment for the infective using optimal control theory. Numerical simulation was carried out in order to illustrate the analytic results.

Entities:  

Year:  2015        PMID: 32255874      PMCID: PMC7108779          DOI: 10.1063/1.4915640

Source DB:  PubMed          Journal:  AIP Conf Proc        ISSN: 0094-243X


  4 in total

1.  Optimal strategy for controlling the spread of HIV/AIDS disease: a case study of South Africa.

Authors:  Tunde T Yusuf; Francis Benyah
Journal:  J Biol Dyn       Date:  2011-10-26       Impact factor: 2.179

2.  Backward bifurcation and optimal control in transmission dynamics of west nile virus.

Authors:  Kbenesh W Blayneh; Abba B Gumel; Suzanne Lenhart; Tim Clayton
Journal:  Bull Math Biol       Date:  2010-01-07       Impact factor: 1.758

3.  Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency.

Authors:  Kenneth A Lichtenstein; Carl Armon; Kate Buchacz; Joan S Chmiel; Anne C Moorman; Kathleen C Wood; Scott D Holmberg; John T Brooks
Journal:  J Acquir Immune Defic Syndr       Date:  2008-01-01       Impact factor: 3.731

4.  Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture.

Authors:  David Marchant; Stuart J D Neil; Áine McKnight
Journal:  J Gen Virol       Date:  2006-02       Impact factor: 3.891

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.